semaglutide risk of cancer Popular obesity medications significantly lower overall risk, study finds. The breakthrough class obesity medications, including GLP-1 receptor agonists like and dual GLP-1/GIP receptor agonists like tirzepatide, continue to make Does semaglutide cause cancer? An
Description
In a phase 3 clinical trial, tirzepatide reduced 14.9% of body weight with a 5 mg dose, 19.5% with a 10 mg dose, and 20.9% with a 15 mg dose of tirzepatide
Safety and clinical oversight The higher 7.2 mg dose showed a safety profile consistent with earlier studies, with no new concerns identified in the early responder group
Always consult your healthcare provider before starting, stopping, or changing any medication or treatment plan
Almost 50% of the United States population has a chronic disease, and 86% of healthcare costs are attributed to treating them
